Abstract: As trategy for the preparation of homogeneous antibody-drug conjugates (ADCs) containing multiple payloads has been developed. This approach utilizes sequential unmasking of cysteine residues with orthogonal protection to enable site-specific conjugation of each drug. In addition, because the approach utilizes conjugation to native antibody cysteine residues,itiswidely applicable and enables high drug loading for improved ADC potency.T oh ighlight the benefits of ADC dual drug delivery,t his strategy was applied to the preparation of ADCs containing two classes of auristatin druglinkers that have differing physiochemical properties and exert complementary anti-cancer activities.D ual-auristatin ADCs imparted activity in cell line and xenograft models that are refractory to ADCs comprised of the individual auristatin components.This work presents afacile method for construction of potent dual-drug ADCs and demonstrates howdelivery of multiple cytotoxic warheads can lead to improved ADC activities.L astly,w ea nticipate that the conditions utilized herein for orthogonal cysteine unmasking are not restricted to ADCs and can be broadly utilized for site-specific protein modification.
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Antibody-drug conjugates (ADCs) combine the tumor targeting specificity of monoclonal antibodies with the potent cell-killing activity of cytotoxic warheads.T here has been asurge of interest in designing new ADC formats due in part to the recent clinical success of ADCs,which includes the approvals of brentuximab vedotin (ADCETRIS) in relapsed Hodgkin lymphoma and anaplastic large-cell lymphoma, and ado-trastuzumab mertansine (KADCYLA) in HER2-positive metastatic breast cancer.
[1] Most of these new methodologies have focused on addressing some of the shortcomings of existing clinical molecules,s uch as heterogeneous drug loading, limited drug-linker stability,a nd warheads with activities that are restricted to as ubset of cancer types.T o enable improved ADCs,much notable advancement has been made in the field. These include site-specific drug-linker conjugation strategies that enable homogeneous loading, drug-linker attachment modalities with improved stability, potent new payloads,a nd linker strategies that utilize alternative release mechanisms. [1c, 2] Almost all effective cancer chemotherapy utilizes complementary drug combinations designed to overcome differential drug sensitivities within heterogeneous tumor cell populations. [3] This strategy has recently also been applied to ADCs,w hich are now being tested in combination with unconjugated, clinically approved anticancer drugs.
[4] In addition, emerging clinical and preclinical data for ADCs has demonstrated that insensitivity to ap articular ADC can be overcome through delivery of an alternative warhead using the same antibody. [5] Fort hese reasons,c omplementary drug payloads within an ADC would likely constitute asignificant advancement in the field of targeted drug delivery.H ere,w e describe an accessible dual-cytotoxic drug conjugate technology for native,non-engineered IgGs and demonstrate the first use of orthogonal thiol protecting groups on afolded protein.
We present the first data demonstrating that dual-drug ADCs have enhanced in vitro and in vivo activities compared to conventional ADCs.
Thec onjugation of two different highly potent auristatin molecules with complementary physiochemical properties presents an intriguing route to enhance ADC activity on heterogeneous cell populations.C ommonly employed auristatin drug-linkers include mc-MMAF (1), mc-vc-MMAF (2), and mc-vc-MMAE (3). Ther eleased drug from am c-vc-MMAE drug linker, monomethyl auristatin E( MMAE), is cell permeable and exhibits bystander activity,orthe killing of neighboring antigen-negative cells. [7] However,M MAE is also as ubstrate for MDR exporters and has diminished activity on cells with high pump expression. [8] Conversely, MMAF and cys-mcMMAF,released from mc-vc-MMAF and mc-MMAF ADCs,r espectively,a re not susceptible to drug export and retain activity on MDR(+ +)cells but are minimally cell permeable.
[7b, 9] Thus,t hey do not exhibit bystander activity and have little activity on antigen-negative tumor cells.W ereasoned that combining the features of these types of drugs could provide complementary activities on cancers, yielding ADCs with enhanced cytotoxicity profiles.
We prioritized two main criteria for dual-drug conjugation when initiating this work:t he methodology must result in homogeneous and site-specific loading of both drugs,a nd it should not require engineered antibodies or enzyme-mediated conjugations so that drug combinations could be screened on an array of IgGs,i ncluding commercial antibodies and hybridoma antibody libraries.T od ate,o nly asingle example of amulti-drug conjugate has been reported, but this work was conducted on an antibody Fabfragment and required the genetic introduction of an engineered cysteine residue to enable site-specific discrimination of conjugation sites. [10] An umber of other approaches for the site-specific conjugation of two separate agents to an antibody have been presented (recently reviewed in Ref. [11] ), but most of these methods require specialized reagents including site-specific amino acid mutations or custom enzymes,a nd sometimes require two distinct conjugation handles.A ll of these factors increase the complexity of reagents required to generate and screen multi-drug ADCs.O ne method that fit our criteria utilized pyridazine-dione re-bridging of native antibody disulfides followed by dual-click functionalization to construct al argely homogeneous product, but this method was only used to create afluorophore-drug antibody conjugate. [12] Our solution towards creating ag eneral approach was to utilize adrug carrier that can be conjugated to native antibody interchain disulfides through maleimide chemistry.The multiplexing drug carrier (4,F igure 1B)b ears two orthogonally protected cysteine residues that can be sequentially unmasked and conjugated with different drug linkers.U sing this approach, an ADC is produced that is homogeneous and bears an average of 16 total drugs,s plit evenly between the two drug linkers.The carrier utilizes two recent advancements for the construction of ADCs with improved pharmacological activity:aself-stabilizing maleimide (mDPR) to minimize drug-linker deconjugation in vivo, [2a] and aPEG 24 stretcher to enable high drug loading without concomitant hydrophobicity-induced ADC aggregation. [6] To carry out this intended strategy,weneeded to identify two distinct cysteine protecting groups that could be unmasked selectively in aqueous conditions without affecting antibody structure or causing ADC aggregation. Cysteine residues bearing reducible disulfide protecting groups,such as S-(tert-butyl) or S-(isopropyl) disulfides can be readily removed with reducing agents and have been used extensively for selective peptide modification. [13] We reasoned that these types of protecting groups would be attractive for a2 -step conjugation on afolded protein because they can be removed using tris-(2-carboxylethyl) phosphine (TCEP) under mild aqueous conditions,w hich are the same conditions used to reduce native antibody interchain disulfides.
To identify as econd protecting group for our carrier,w e screened for protecting groups that were stable to TCEP reduction but could be removed rapidly in aqueous conditions.T hrough this work, we identified aqueous conditions for the deprotection of acetamidomethyl (Acm)-protected cysteines.
[13b] Specifically,m aleimidocaproyl-Cys(Acm) was synthesized and conjugated to the interchain cysteines of the CD30-directed antibody cAC10 and subjected to potential deprotection conditions.W efound that the Acm group could be readily removed with approximately 5-6 molar equivalents (per thiol) of aqueous mercury acetate in 45 min at neutral pH ( Figure S1 in the Supporting Information). Subsequent removal of Cys-bound mercury using an immobilized thiol source (Quadrasil MP resin) was required to liberate the thiol for drug-linker conjugation ( Figure S2) . Importantly,the Acm group was stable to TCEP,e nsuring that the two protecting groups could be removed orthogonally.I na ddition, the conditions for Acm removal do not impact antibody disulfide integrity ( Figure S3 ), indicating that these conditions could be applied more generally for bio-orthogonal protein modification. While the Acm protecting group has been used extensively in peptide synthesis and protein semi-synthesis, [13b, 14] to our knowledge this is the first use of an Acmmasked Cys on afolded protein.
Drug carrier 4,bearing Cys(SiPr) and Cys(Acm) residues, was synthesized by solid-phase peptide synthesis and conjugated to cAC10. Thec onjugation process and resulting analytics for an ADC bearing drug-linkers 1 and 3 are shown in Figure 2 . First, the antibody interchain disulfides were reduced using 12 equiv of TCEP at pH 7.4 and 37 8 8Cf or 90 min. Subsequently,t he free sulfhydryls were each reacted with atwo-fold excess of carrier 4,yielding aconjugate with 8 carriers per antibody.T he reaction status was checked using ar eversed-phase ultra-performance liquid chromatographymass spectrometry (UPLC-MS) method that separates light and heavy chain species based on drug (or carrier) loading. . Drug-linkers and carriers for conjugation to mAbs. A) Maleimide-auristatin drug-linkers used in this study.B )Amultiplexing drug carrier 4 bearing Cys(SiPr) and Cys(Acm) groups that can be unmasked using orthogonalconditions. The carrier also contains aPEG 24 group to mask drug-linker hydrophicity [6] and aself-stabilizing maleimide (mDPR) [2a] for antibody attachment. C) Homogeneous dualdrug ADCs prepared using 4 bear 16 total drugs, split evenly (8+ +8) between the two component drugs.
This analysis confirmed that the conjugate eluted as as ingle light and heavy chain, each with the expected mass,indicating full conversion to ah omogeneous conjugate with 8c arriers per antibody (Figure 2A ). Thec AC10-carrier conjugate was then subjected to reduction with 10 equiv of TCEP for 45 min at 37 8 8Ct or emove the S-(isopropyl) disulfides.A nalysis by UPLC-MS confirmed that the reaction was complete (Figure S4) . Theu n-masked Cys residues were then conjugated with mc-MMAF (1)using a1.5 equiv of drug-linker per thiol. UPLC-MS analysis indicated conversion to an 8-loaded conjugate within 15 min. In order to conjugate the second drug-linker, the Acm protecting groups were un-masked using 5-6 equiv of aqueous Hg(OAc) 2 per thiol. Complete Acm un-masking was observed by UPLC-MS within 45 min at room temperature and neutral pH. Prior to addition of the drug-linker, excess Hg 2+ was captured using Quadrasil MP resin. Addition of 2.0 equiv of mc-vc-MMAE drug-linker (3) per thiol resulted in complete reaction in 15 min, as assessed by UPLC-MS.A ss hown in Figure 2 , each step of the coconjugation process resulted in clean conversion to as ingle light and heavy chain, demonstrating high levels of homogeneity with an average of 16 drugs/mAb.T he conjugate was analyzed by size-exclusion chromatography (SEC), which demonstrated that the conjugate was 98 %m onomeric (Figure S6) . Lastly,c ell binding analysis demonstrated that the conjugation process did not significantly impact cAC10 binding to CD30 ( Figure S7) .
In order to demonstrate the benefits of the approach described here,wecompared the in vitro and in vivo activities of dual-auristatin ADCs compared to 8-loaded cAC10-1, cAC10-2,o rc AC10-3 ADCs on cells with differential sensitivities to the individual drugs.All ADCs tested, including single-drug ADCs,e mployed drug-linker conjugation to carrier 4,a nd for the single-drug ADCs,t he second Cys residue on carrier 4 was capped with N-ethyl maleimide.W e first investigated the activity of ADCs in systems with high MDR expression, where MMAE can have impaired activity due to drug transport. Cytotoxicity experiments were conducted in vitro on ac AC10-vc-MMAE resistant cell line, DEL-BVR ( Figure 3A ). This cell line was generated after prolonged exposure of the DEL anaplastic large cell lymphoma (ALCL) cell line to cAC10-3,w hich renders it refractory to treatment with mc-vc-MMAE ADCs due to high MDR levels.O nt his cell line,c AC10-3 was completely inactive at the highest concentrations tested (up to 2000 ng mL À1 ), whereas both cAC10-2 and cAC10-(2 + 3) retained potent activity (IC 50 < 1.0 ng mL À1 ). In contrast, all three conjugates were highly active on parental DEL, with IC 50 values below 1.5 ng mL À1 .T he dual-drug conjugate was most potent on this cell line,o wing to the increase in drug loading from 8to16drugs per antibody.All three conjugates were inactive on CD30(À)U -266 cells,d emonstrating that activity was not due to insufficient drug-linker stability. Encouraged by these results,w ee xamined ADC activity in am ouse xenograft model using the DEL-BVR cell line ( Figure 3B ). At ad ose of 3mgkg À1 ,c AC10-3 showed no activity.M eanwhile,t he dual drug conjugate cAC10-(2 + 3) displayed potent antitumor activity at the same dose,resulting in 3/5 cures.T his activity was slightly better than cAC10-2, which provided 1/5 cures.T hese results demonstrate that dual-drug ADCs prepared using this approach are active in vivo and that insensitivity to MDR can be overcome through addition of acomplementary payload.
We next sought to enhance the activity of MMAF-based ADCs by adding the cell permeability and bystander activity of MMAE. In this case,cAC10-1,cAC10-3,and cAC10(1 + 3) were tested in an in vitro model of bystander activity,w here MMAF drugs have little or no activity (Figure 4) . In this assay,C D30(À)U -266 multiple myeloma cells that express luciferase are cultured in a1:1 mixture with CD30(+ +)L540cy cells.A fter treatment with the ADCs,t he viability of the U266luc cells was assessed by decrease in luciferase activity, which would reflect the diffusion of active drug released within the CD30(+ +)L540cycells.Inthis model, cAC10-1 had minimal activity on the mixed co-culture,s ince the released drug, cys-mc-MMAF,i sn ot cell permeable.M eanwhile, cAC10-3 displayed potent bystander activity with an IC 50 of 3.9 ng mL À1 ,a sd id cAC10-(1 + 3). All three conjugates were inactive on CD30(À)U-266luc cells,and anon-binding ADC bearing (1 + 3)had no activity on L540cycells,demonstrating immunological specificity ( Figure S8 ). Encouraged with these in vitro results,w et ested the same conjugates in an in vivo model that has heterogeneous CD30 expression. Thex enograft model consists of an admixed population of CD30(+ +) and CD30(À)K arpas 299 cells.
[7b] In this model, cAC10-1 showed only am odest tumor growth delay when dosed at 3mgkg À1 .M eanwhile,t reatment with both cAC10-3 and cAC10-(1 + 3)p rovided ar obust antitumor response at the same dose,r esulting in 5/5 cures and 4/5 cures,r espectively. Importantly,t hese results combined with those from the DEL-BVR xenograft ( Figure 3B )d emonstrate that dualauristatin ADCs are active on tumors that are both high in MDR expression and have heterogeneous antigen levels.
In conclusion, we have developed afacile method for the construction of homogenous dual-drug ADCs.This method is broadly applicable to av ariety of antibodies,s ince recombinant technologies to achieve site-specificity are not required. Thei nherent flexibility of this approach enables rapid screening of antibody and drug-linker libraries to identify dual-drug ADCs with improved activities.W ehave provided biological data demonstrating that dual-drug ADCs are able to kill multiple types of cell populations,i ncluding both cells that lack CD30 antigen in mixed cell line models and those that possess MDR activity.T herefore,m ulti-drug ADCs are active on cell types that are refractory to either of the individual component drugs.T his work highlights the potential for an ew class of targeted therapeutics where multiple drugs with complementary or synergistic activities are simultaneously delivered.
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